AU2018387829B2 - Bispecific antigen binding construct - Google Patents

Bispecific antigen binding construct Download PDF

Info

Publication number
AU2018387829B2
AU2018387829B2 AU2018387829A AU2018387829A AU2018387829B2 AU 2018387829 B2 AU2018387829 B2 AU 2018387829B2 AU 2018387829 A AU2018387829 A AU 2018387829A AU 2018387829 A AU2018387829 A AU 2018387829A AU 2018387829 B2 AU2018387829 B2 AU 2018387829B2
Authority
AU
Australia
Prior art keywords
val
ser
pro
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018387829A
Other languages
English (en)
Other versions
AU2018387829A1 (en
Inventor
Christophe Blanchetot
Sebastian VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64959348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018387829(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2018387829A1 publication Critical patent/AU2018387829A1/en
Application granted granted Critical
Publication of AU2018387829B2 publication Critical patent/AU2018387829B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018387829A 2017-12-22 2018-12-21 Bispecific antigen binding construct Active AU2018387829B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609523P 2017-12-22 2017-12-22
US62/609,523 2017-12-22
PCT/EP2018/086755 WO2019122409A1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Publications (2)

Publication Number Publication Date
AU2018387829A1 AU2018387829A1 (en) 2020-05-07
AU2018387829B2 true AU2018387829B2 (en) 2024-12-19

Family

ID=64959348

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018387829A Active AU2018387829B2 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Country Status (9)

Country Link
US (2) US12071486B2 (enExample)
EP (2) EP3728328B1 (enExample)
JP (2) JP7657591B2 (enExample)
CN (1) CN111448217A (enExample)
AU (1) AU2018387829B2 (enExample)
CA (1) CA3079793A1 (enExample)
DK (1) DK3728328T5 (enExample)
IL (1) IL274676A (enExample)
WO (1) WO2019122409A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210144837A (ko) * 2019-03-28 2021-11-30 에이비 스튜디오 인코포레이티드 이종다량체 단백질 및 이의 사용 방법
EP4090687A4 (en) * 2020-01-19 2024-02-21 Nanjing GenScript Biotech Co., Ltd. Multispecific anti-claudin-18.2 constructs and uses thereof
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
EP4652195A2 (en) * 2023-01-20 2025-11-26 Invetx, Inc. Bispecific binding agents for use in companion animals

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331527A1 (en) * 2009-06-26 2010-12-30 Regeneron Pharmaceuticals, Inc. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
WO2013064701A2 (en) * 2011-11-03 2013-05-10 Argen-X B.V. Bispecific antibodies and methods for isolating same
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
US20140363426A1 (en) * 2013-03-15 2014-12-11 Gregory Moore Heterodimeric proteins
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
WO2016086189A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
UY31504A1 (es) 2007-11-30 2009-07-17 Construcciones de union de antigenos
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
JP5497887B2 (ja) 2009-04-07 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−２／抗ｃ−Ｍｅｔ抗体
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
EA201791693A1 (ru) 2011-03-25 2018-05-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
ES2728301T3 (es) 2012-03-13 2019-10-23 Novimmune Sa Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2013352812B2 (en) 2012-11-27 2019-06-20 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CA2903258C (en) 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
US10882922B2 (en) 2016-04-13 2021-01-05 Sanofi Trispecific and/or trivalent binding proteins
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331527A1 (en) * 2009-06-26 2010-12-30 Regeneron Pharmaceuticals, Inc. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
WO2013064701A2 (en) * 2011-11-03 2013-05-10 Argen-X B.V. Bispecific antibodies and methods for isolating same
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
US20140363426A1 (en) * 2013-03-15 2014-12-11 Gregory Moore Heterodimeric proteins
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
WO2016086189A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies

Also Published As

Publication number Publication date
EP4495142A2 (en) 2025-01-22
EP3728328B1 (en) 2024-10-23
US12071486B2 (en) 2024-08-27
US20190218310A1 (en) 2019-07-18
EP4495142A3 (en) 2025-05-07
AU2018387829A1 (en) 2020-05-07
WO2019122409A1 (en) 2019-06-27
DK3728328T5 (da) 2025-02-17
JP7657591B2 (ja) 2025-04-07
US20240368311A1 (en) 2024-11-07
DK3728328T3 (da) 2025-01-02
CA3079793A1 (en) 2019-06-27
JP2021506310A (ja) 2021-02-22
JP2023139025A (ja) 2023-10-03
IL274676A (en) 2020-06-30
CN111448217A (zh) 2020-07-24
EP3728328A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
RU2570633C2 (ru) Три- или тетраспецифические антитела
US20240368311A1 (en) Bispecific antigen binding construct
TWI576353B (zh) 多重特異性抗體
CN102803295B (zh) 双特异性、四价抗原结合蛋白
CN103068846B (zh) 包含二硫键稳定性Fv片段的双特异性抗体
EP2970435B1 (en) Methods for producing fabs and bi-specific antibodies
WO2017143840A1 (zh) 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
WO2013164325A1 (en) Multispecific antigen binding proteins
CN113395978A (zh) 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
WO2024092038A2 (en) Anti-cd3 antibodies
HK1170495B (en) Tri- or tetraspecific antibodies
HK1174645B (en) Bispecific, tetravalent antigen binding proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)